Skip to main content

Table 2 Subject demographic information and data

From: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Demographics

Neuropathology

Imaging

Case

Age

Sex

Timea

Dementiab

mCsc

d

ADe

CERADf

Braakg

Amyloid phaseh

Diagnosesi

SUVRj

PETmajk

1

73

F

360

Yes

0.0

n.d.

Normal

-

II

1

Inf TDPl

1.13

Normal

2

84

M

17

Yes

0.0

0.3

Normal

-

I

0

Normal

1.18

Normal

3

83

M

568

No

0.0

n.d.

Normal

-

IV

1

LBD

1.17

Normal

4

91

M

130

Yes

0.0

0.9

Normal

-

0

0

PSP VAD

1.34

Normal

5

63

M

433

No

0.0

n.d.

Low

-

II

1

PSP

1.42

Normal

6

76

F

145

Yes

0.0

n.d.

Normal

-

II

1

LBD VAD

1.22

Normal

7

70

M

16

No

0.0

n.d.

Normal

-

0

0

Normal

1.44

Normal

8

67

M

32

No

0.0

n.d.

Normal

-

I

0

Normal

1.37

Normal

9

80

M

131

Yes

0.0

n.d.

NA

-

III

0

TPD

1.26

Normal

10

61

F

34

No

0.0

n.d.

Normal

-

0

1

Normal

1.67

Normal

11

65

F

393

No

0.0

n.d.

Normal

-

III

1

AC

1.21

Normal

12

60

M

374

No

0.0

n.d.

Low

-

III

1

VAD

1.34

Normal

13

74

M

170

Yes

0.1

8.1

Normal

-

0

2

VAD

1.12

Normal

14

66

M

155

No

0.1

n.d.

Normal

-

0

0

AC

1.3

Normal

15

76

F

10

Yes

0.1

0.2

Normal

-

I

2

Normal

1.56

Normal

16

63

M

12

No

0.1

n.d.

Normal

-

0

0

Normal

1.6

Normal

17

73

F

105

Yes

0.5

0.4

Normal

-

V

1

TPD

1.34

Normal

18

90

F

115

Yes

0.0

n.d.

Low

S

III

1

Inf AS

1.4

Normal

19

89

F

78

No

0.3

n.d.

Int

S

IV

2

CAA AD

1.25

Normal

20

82

F

24

Yes

0.4

0

Low

S

III

1

LBD

1.72

Normal

21

92

F

210

Yes

0.7

n.d.

Normal

S

II

4

CAA PD

1.55

Normal

22

84

F

69

Yes

1.1

1

Int

S

II

2

Inf

1.36

Normal

23

72

M

142

Yes

1.3

n.d.

Normal

S

0

3

FTD

1.01

Normal

24

87

F

76

Yes

1.4

2

Low

S

I

3

VAD

1.57

Normal

25

87

F

137

Yes

1.5

n.d.

Normal

S

0

2

AC AS

1.53

Normal

26

60

M

11

Yes

1.7

n.d.

Low

S

II

4

CAA

1.08

Normal

27

81

M

189

No

1.8

n.d.

Normal

S

I

4

ND

1.6

Normal

28

92

F

212

Yes

2.1

n.d.

Int

S

III

3

TDPl

1.26

Normal

29

87

F

131

Yes

1.4

8.1

Low

S

IV

5

LBD

1.95

Abnormal

30

96

F

630

Yes

1.9

n.d.

High

S

VI

5

AD

2.15

Abnormal

31

92

F

132

Yes

1.9

n.d.

Low

S

III

4

LBD

2.72

Abnormal

32

89

F

311

Yes

2.0

n.d.

Int

S

III

5

AD CAA VAD

2.33

Abnormal

33

88

F

118

Yes

2.1

n.d.

Low

S

II

4

Inf LBD AS

3.14

Abnormal

34

80

M

2

Yes

2.1

7.6

High

S

VI

5

AD LBD

2.1

Abnormal

35

94

F

19

Yes

2.1

7.7

Int

S

III

5

AD

1.95

Abnormal

36

88

F

329

Yes

2.1

n.d.

High

S

V

5

AD

2.84

Abnormal

37

74

F

550

Yes

2.8

n.d.

High

S

VI

5

AD

2.23

Abnormal

38

86

M

19

No

1.4

2.3

Int

M

III

3

AD

1.45

Normal

39

75

M

64

Yes

1.4

1.4

Int

M

II

3

Inf LBD

1.23

Normal

40

84

M

349

Yes

1.6

n.d.

Int

M

V

3

AD LBD AS VAD Ath

1.73

Normal

41

93

M

323

No

1.9

n.d.

Low

M

II

3

LBD

1.36

Normal

42

87

M

22

No

2.7

4

Int

M

IV

4

AD

2.04

Normal

43

86

F

193

Yes

0.3

9.4

Low

M

III

4

LBD

2.07

Abnormal

44

76

M

84

Yes

1.5

10.3

Low

M

II

3

LBD

1.87

Abnormal

45

75

M

373

Yes

1.6

n.d.

Int

M

IV

5

AD CAA

1.48

Abnormal

46

82

F

127

Yes

1.7

n.d.

Int

M

IV

4

AD LBD

2.32

Abnormal

47

86

M

395

Yes

1.8

n.d.

High

M

V

5

AD

2.83

Abnormal

48

93

F

500

Yes

1.8

n.d.

Int

M

V

3

AD AS VAD

1.6

Abnormal

49

84

M

45

Yes

1.8

n.d.

Low

M

II

3

VAD

1.85

Abnormal

50

93

F

243

Yes

1.9

n.d.

High

M

VI

5

AD

2.72

Abnormal

51

93

F

755

Yes

2.0

n.d.

High

M

IV

5

AD

2.2

Abnormal

52

80

M

276

Yes

2.0

n.d.

High

M

VI

4

AD

2.33

Abnormal

53

90

M

308

Yes

2.1

n.d.

Low

M

II

4

LBD

2.19

Abnormal

54

78

M

62

Yes

2.1

10.1

High

M

VI

5

AD LBD

2.86

Abnormal

55

86

F

747

Yes

2.1

n.d.

Int

M

IV

3

AD CAA

1.81

Abnormal

56

73

F

295

No

2.2

n.d.

Low

M

I

3

LBD

1.76

Abnormal

57

87

F

318

Yes

2.2

n.d.

Int

M

III

5

AD AS VAD Ath

2.26

Abnormal

58

88

F

266

Yes

2.2

n.d.

Int

M

III

4

AD LBD

1.91

Abnormal

59

88

F

79

Yes

2.3

17.6

High

M

VI

5

AD

1.67

Abnormal

60

93

F

396

Yes

2.3

n.d.

High

M

VI

5

AD CAA Inf

3.08

Abnormal

61

85

M

60

No

2.4

14.7

High

M

VI

5

CAA AD VAD

2.81

Abnormal

62

91

M

30

Yes

2.4

2.9

High

M

V

4

AD

1.86

Abnormal

63

95

F

15

Yes

2.4

7.5

High

M

VI

5

AD

1.89

Abnormal

64

79

M

42

No

2.4

n.d.

Int

M

III

4

CAA mCa AD

2.44

Abnormal

65

81

F

184

Yes

2.5

n.d.

Int

M

IV

3

LBD

1.66

Abnormal

66

84

F

193

Yes

2.6

n.d.

High

M

V

5

AD

2.4

Abnormal

67

72

M

268

Yes

2.7

n.d.

High

M

VI

5

AD VAD

2.07

Abnormal

68

63

M

342

Yes

2.8

n.d.

High

M

VI

5

AD AS VAD

1.94

Abnormal

69

89

F

115

Yes

3.0

n.d.

High

M

VI

5

AD CAA LBD AS

2.39

Abnormal

70

83

F

611

Yes

1.8

n.d.

Low

F

I

4

AS CAA VAD TDPl

1.87

Normal

71

84

F

189

No

1.7

n.d.

Int

F

0

3

CAA Inf VAD AD

2.02

Abnormal

72

82

M

397

Yes

1.9

n.d.

High

F

VI

5

AD CAA VAD

2.41

Abnormal

73

86

F

155

Yes

2.0

n.d.

High

F

V

5

AD

2.43

Abnormal

74

93

F

594

Yes

2.0

n.d.

High

F

IV

5

AD

2.46

Abnormal

75

90

F

538

Yes

2.0

n.d.

High

F

VI

4

AD CAA AS VAD

2.78

Abnormal

76

78

F

180

Yes

2.2

n.d.

Normal

F

0

4

MSA

2.03

Abnormal

77

93

F

200

Yes

2.2

n.d.

High

F

V

5

AD AS CAA LBD VAD

2.42

Abnormal

78

78

F

125

Yes

2.2

n.d.

High

F

VI

5

AD LBD

2.12

Abnormal

79

72

M

1

Yes

2.4

11.4

High

F

VI

5

AD

2.37

Abnormal

80

76

F

27

Yes

2.4

n.d.

High

F

VI

5

AD CAA

1.83

Abnormal

81

77

F

11

Yes

2.4

8.9

High

F

VI

4

AD

1.59

Abnormal

82

91

F

55

Yes

2.4

11.2

High

F

VI

4

AD CAA

2.2

Abnormal

83

81

M

204

Yes

2.4

n.d.

High

F

VI

4

AD CAA LBD

2.41

Abnormal

84

82

M

15

Yes

2.5

6.9

High

F

VI

4

AD CAA

2.23

Abnormal

85

83

M

34

Yes

2.5

8.5

High

F

VI

5

AD

2.6

Abnormal

86

90

F

51

Yes

2.5

12.2

High

F

VI

4

AD

2.35

Abnormal

87

73

F

27

Yes

2.5

9.6

High

F

VI

5

AD

2.23

Abnormal

88

87

M

1

Yes

2.5

7.8

High

F

IV

4

AD CAA

2.1

Abnormal

89

89

F

768

Yes

2.5

n.d.

High

F

V

5

AD CAA LBD AS

1.93

Abnormal

90

79

M

332

Yes

2.5

n.d.

High

F

VI

5

AD CAA LBD

2.24

Abnormal

91

80

M

0

Yes

2.6

7.9

High

F

VI

5

AD

2

Abnormal

92

79

F

422

Yes

2.6

n.d.

High

F

V

5

AD CAA LBD AS VAD HC

2.38

Abnormal

93

87

M

106

Yes

2.6

n.d.

High

F

VI

5

AD

2.2

Abnormal

94

66

F

139

Yes

2.7

n.d.

High

F

VI

5

AD

2.37

Abnormal

95

84

M

181

Yes

2.7

n.d.

High

F

V

4

AD LBD

2.75

Abnormal

96

87

M

769

Yes

2.7

n.d.

High

F

VI

5

AD CAA LBD VAD

2.5

Abnormal

97

71

M

305

Yes

2.7

n.d.

High

F

V

5

AD CAA

2.47

Abnormal

98

72

F

565

Yes

2.7

n.d.

High

F

VI

5

AD CAA LBD

2.58

Abnormal

99

85

M

846

Yes

2.8

n.d.

High

F

VI

5

AD VAD

2.01

Abnormal

100

84

F

198

Yes

2.8

6.3

High

F

VI

4

AD

1.48

Abnormal

101

85

F

436

Yes

2.9

n.d.

High

F

VI

5

AD

2.65

Abnormal

102

75

F

66

Yes

2.9

10.6

High

F

VI

5

AD

2.47

Abnormal

103

87

M

493

No

2.9

n.d.

High

F

IV

5

CAA LBD AD

2.42

Abnormal

104

86

F

127

Yes

3.0

n.d.

High

F

VI

5

AD

2.9

Abnormal

105

81

M

171

Yes

3.0

n.d.

High

F

VI

5

AD

2.34

Abnormal

106

63

M

562

Yes

3.0

n.d.

High

F

VI

5

AD

2.72

Abnormal

  1. Subjects are ranked by CERAD neuritic plaque frequency and then by mCERADSOT. AC ageing changes, AD Alzheimer’s disease (high or intermediate likelihood by National Institute of Ageing-Reagan Institute criteria), AS arteriosclerosis or arteriolosclerosis, Ath atherosclerosis, CAA cerebral amyloid angiopathy, FTD frontotemporal lobar degeneration, HC hydrocephalus, Inf infarct, LBD Lewy body disease, mCa metastatic carcinoma, MSA multisystem atrophy, ND neurofibrillary degeneration, PD Parkinson’s disease, PSP progressive supranuclear palsy, SUVR standard retention value ratio, TDP+ TDP43 immunopositivity, TPD tangle-predominant dementia, VSD vascular disease not otherwise specified
  2. aTime between PET imaging and death in days
  3. bDementia recorded in the study medical history
  4. cmCERADSOT; maximal regional mean score determining Standard of Truth assignation as abnormal if > 1.5
  5. dPercentage area of grey matter stained positively by amyloid β immunohistochemistry (4G8) determined only on a subset (32 subjects) of the cohort
  6. eAlzheimer’s Disease likelihood recorded by a neuropathologist against National Institute of Ageing-Reagan Institute criteria [26] but blinded to dementia status
  7. fCERAD neuritic plaque frequency recorded during neuropathology diagnoses (N: none; S: sparse; M: moderate; F: frequent)
  8. gBraak neurofibrillary tangle stage recorded during neuropathology diagnosis
  9. hAmyloid phase [25, 58]
  10. iNeuropathologist’s diagnoses blinded to clinical data. Note: co-incident plaque burden may be present in non-AD diagnoses
  11. jComposite SUVR determined from bilateral measures and normalised to cerebellum as the reference region
  12. kMajority PET image evaluation
  13. lTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed on all subjects